A Jefferies conference dispatch spotlights three different biotech bets:
Latent Labs’ use of AI, Relay Therapeutics’ ambitions for its PI3Kα drug, and Biohaven’s extracellular protein-degrader platform.
Relay is advancing zovegalisib, a mutant-selective PI3Kα inhibitor, across breast cancer and vascular-anomaly programs. The company has described three pivotal trials and is preparing for possible commercialization; outcomes still depend on clinical and regulatory success.
Biohaven’s MoDE and TRAP approaches aim to remove disease-driving proteins circulating outside cells. The molecules direct targets toward the liver for breakdown, with programs focused on harmful antibodies in autoimmune diseases. The company has reported early clinical biomarker and patient data, but these approaches remain under development.
The available search results identify Latent Labs as part of the dispatch’s AI discussion but do not provide enough detail to reliably summarize its specific claims or announcements.
Sources:
Relay Therapeutics at Jefferies: cash, trials and a dual-track push By Investing.com
Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust ...
Biohaven Reports Positive Clinical Biomarker and Patient Data ...
Positive Degrader Data with Rapid, Deep, and Selective ...
Smillin — Daily AI & Healthcare Tech TLDR
Biohaven Enters Strategic Licensing Agreement with Ono ...
Relay Therapeutics, Inc. (RLAY) June 3, 2026 Earnings Call ...